stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Gross margin
Neurocrine Biosciences, Inc.'s gross margin over the twelve months to 30 September 2026 was 97.8%, down 0.4 percentage points from fiscal 2025 (98.2%). Over the past ten years it has ranged from 97.9% (fiscal 2023) to 100.0% (fiscal 2016); the current reading is higher than 18% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 53.5% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 98.2% | (0.38) |
| FY2024 | 98.6% | 0.66 |
| FY2023 | 97.9% | (0.54) |
| FY2022 | 98.4% | (0.30) |
| FY2021 | 98.7% | (0.29) |
| FY2020 | 99.0% | (0.03) |
| FY2019 | 99.1% | 0.15 |
| FY2018 | 98.9% | (0.31) |
| FY2017 | 99.2% | (0.78) |
| FY2016 | 100.0% | 0.00 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 97.6% | 0.05 |
| Jun 2026 | 97.6% | (0.73) |
| Mar 2026 | 98.3% | 0.74 |
| Dec 2025 | 97.6% | (0.79) |
| 36 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| NBIX Neurocrine Biosciences, Inc. | 97.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 90.2% |
| UTHR United Therapeutics Corporation compare | 86.3% |
| ALKS Alkermes plc compare | 82.9% |
| ZTS Zoetis Inc. compare | 71.7% |
| HLN Haleon PLC Sponsored ADR compare | 62.2% |
| ELAN Elanco Animal Health Incorporated compare | 55.4% |
| RDY Dr. Reddy's Laboratories Ltd compare | 49.2% |
| VTRS Viatris Inc. compare | 35.3% |
| Drug Manufacturers Specialty & Generic industry median | 53.5% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement